Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 28, 2014
Reporting Period: Event date of October 28, 2014
Nephros, Inc., a Delaware corporation, filed this report to disclose a significant regulatory milestone regarding its product portfolio.
Key Financial Metrics
This filing is a Current Report (Form 8-K) focused on a specific corporate event and does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial indicators.
Material Changes
The material change reported is regulatory in nature rather than financial:
- Regulatory Clearance: On October 28, 2014, the company received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
- Products Affected: DSU-H and SSU-H Ultrafilters.
- Market Expansion: The clearance permits the marketing of these ultrafilters specifically for use in the hospital setting.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) announcing the FDA clearance but does not include forward-looking guidance, financial outlook, or specific management commentary within the body of the 8-K text provided.
Risks and Contingencies: No specific risks, contingencies, or unusual items are detailed in this filing text beyond the standard disclosure of the regulatory event.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the commercial launch timeline for the DSU-H and SSU-H Ultrafilters.
- Confirm the specific scope of the 510(k) clearance to ensure it covers all intended hospital applications.
- Review subsequent filings (e.g., 10-Q or 10-K) to assess the financial impact of this new market access.